Total hip replacements - spoilt for choice or harmful to patients?
This article was originally published in Clinica
Preference should be given to total hip replacement (THR) implants that are backed by published, peer-reviewed long-term clinical trials, recommend surgeons from the Nuffield Orthopaedic Centre, Oxford, UK. In a study (Journal of Bone and Joint Surgery, July), they say that surgeons should use implants which have no published data only in a properly conducted trial or register".
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.